PDGFRA and gastrointestinal stromal tumor: Ripretinib, another PDGFR inhibitor, is a novel type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA and has been approved for the treatment of TKI-refractory GIST [272].